Wan Kei Group (01718) issues profit warning, expecting a net loss of approximately HK$11 million for the interim period, a reversal from profit to loss compared to the same period last year.
Hong Kong conglomerate holding company (01718) announced that the Group expects to achieve not less than... in the six months ending September 30, 2024.
WAN KEI GROUP (01718) announced that the group is expected to incur a net loss of not less than approximately HK$11 million for the six months ending September 30, 2024, compared to a net profit of approximately HK$18.378 million in the same period in 2023.
The announcement stated that the expected net loss is primarily due to impairment losses on financial and contract assets during the reporting period, compared to impairment loss reversals on financial and contract assets in the same period in 2023. Additionally, the increase in selling expenses and general and administrative expenses (including director's remuneration, employee salaries, depreciation of right-of-use assets, and other operating expenses) was attributed to the company's expansion of its existing business to maintain the stability and sustainability of the group's operations.
Related Articles

Shandong Xinhua Pharmaceutical has obtained the registration certificate for concentrated solutions of sodium, potassium, magnesium, and calcium for injections.

Medicalsystem Biotechnology (300439.SZ) obtained a medical device registration certificate.

Teyi Pharmaceutical Group (002728.SZ): Glucosamine sulfate capsules have obtained a drug registration certificate.
Shandong Xinhua Pharmaceutical has obtained the registration certificate for concentrated solutions of sodium, potassium, magnesium, and calcium for injections.

Medicalsystem Biotechnology (300439.SZ) obtained a medical device registration certificate.

Teyi Pharmaceutical Group (002728.SZ): Glucosamine sulfate capsules have obtained a drug registration certificate.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


